ALK and non-small cell lung carcinoma: Initially developed as an ALK inhibitor due to its strong inhibitory activity against ALK (IC50 = 2.4 nM), conteltinib demonstrated manageable safety, favorable pharmacokinetic properties, and anticancer effects in patients with advanced ALK-positive NSCLC in a phase I human clinical study (Xing et al., 2022).